JP2018528776A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528776A5
JP2018528776A5 JP2018513633A JP2018513633A JP2018528776A5 JP 2018528776 A5 JP2018528776 A5 JP 2018528776A5 JP 2018513633 A JP2018513633 A JP 2018513633A JP 2018513633 A JP2018513633 A JP 2018513633A JP 2018528776 A5 JP2018528776 A5 JP 2018528776A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528776A (ja
JP7020687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051847 external-priority patent/WO2017048902A1/en
Publication of JP2018528776A publication Critical patent/JP2018528776A/ja
Publication of JP2018528776A5 publication Critical patent/JP2018528776A5/ja
Application granted granted Critical
Publication of JP7020687B2 publication Critical patent/JP7020687B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513633A 2015-09-15 2016-09-15 Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用 Expired - Fee Related JP7020687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218990P 2015-09-15 2015-09-15
US62/218,990 2015-09-15
PCT/US2016/051847 WO2017048902A1 (en) 2015-09-15 2016-09-15 T-cell receptor (tcr)-binding antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2018528776A JP2018528776A (ja) 2018-10-04
JP2018528776A5 true JP2018528776A5 (enExample) 2019-10-17
JP7020687B2 JP7020687B2 (ja) 2022-02-16

Family

ID=56990993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513633A Expired - Fee Related JP7020687B2 (ja) 2015-09-15 2016-09-15 Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用

Country Status (11)

Country Link
US (2) US10633445B2 (enExample)
EP (1) EP3349791A1 (enExample)
JP (1) JP7020687B2 (enExample)
KR (1) KR20180042449A (enExample)
CN (1) CN108430506A (enExample)
AU (2) AU2016323153B2 (enExample)
CA (1) CA2997673A1 (enExample)
HK (1) HK1258218A1 (enExample)
IL (1) IL258009B2 (enExample)
WO (1) WO2017048902A1 (enExample)
ZA (1) ZA202002966B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112795594B (zh) 2013-05-14 2025-09-19 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
JP6640726B2 (ja) 2014-02-14 2020-02-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体及びその製造方法
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
EP3804741A3 (en) 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
CA2977818A1 (en) 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2019084427A1 (en) * 2017-10-27 2019-05-02 Kite Pharma, Inc. T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
WO2020010229A1 (en) * 2018-07-06 2020-01-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
CN109136282A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种hafft1细胞的构建方法
CN114360644B (zh) * 2021-12-30 2024-12-17 山东师范大学 T细胞受体与抗原表位的结合预测方法及系统
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069151A4 (en) 1981-01-14 1983-05-16 Michael G Knickerbocker VALVE ASSEMBLY WITH INTEGRATED PLASTIC SPRING.
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63212525A (ja) 1987-02-28 1988-09-05 Nissei Plastics Ind Co 型締装置
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
CA2471392A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
TWI675044B (zh) * 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US9505849B2 (en) * 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
CN112795594B (zh) 2013-05-14 2025-09-19 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CA2926859A1 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
JP6640726B2 (ja) 2014-02-14 2020-02-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体及びその製造方法
CN106459924A (zh) 2014-04-23 2017-02-22 得克萨斯州大学系统董事会 用于疗法中的嵌合抗原受体(car)及其制备方法
US20170044500A1 (en) 2014-04-24 2017-02-16 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3536707A1 (en) 2014-11-05 2019-09-11 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
EP3804741A3 (en) 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
CA2977818A1 (en) 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2018528776A5 (enExample)
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
US11202828B2 (en) Therapeutic SIRP-α antibodies
JP6840682B2 (ja) 多重特異的抗原結合タンパク質
CN107405397B (zh) 抗tim-3抗体
JP2022137054A (ja) ＮＫｐ４６結合タンパク質の可変領域
JP2022550832A (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
JP2019500892A5 (enExample)
JP2019517773A (ja) 抗ｌａｇ−３抗体
KR20220061982A (ko) 키메라 항원 수용체 및 키메라 항원 수용체를 발현하는 면역 이펙터 세포
JP2018508215A5 (enExample)
JP2015163068A5 (enExample)
JP2019513725A5 (enExample)
CN104822704A (zh) 针对分化簇3(cd3)的人源化的抗体
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
JP2019512207A5 (enExample)
KR20230058074A (ko) Ilt2에 대한 항체 및 이의 용도
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
JP2023524238A (ja) 治療用ＳＩＲＰα抗体
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
JP2018529672A5 (enExample)
AU2015265578B2 (en) Risk-stratification of B-precursor acute lymphoblastic leukemia patients
WO2026008059A1 (en) Anti-dll3 constructs and uses thereof
WO2025201418A1 (en) Engineered immune cells and uses thereof